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Prognosis After Aortic Valve Replacement
With a Bioprosthesis
Predictions Based on Meta-Analysis and Microsimulation
J.P.A. Puvimanasinghe, MBBS, MSc, MD; E.W. Steyerberg, PhD; J.J.M. Takkenberg, MD;
M.J.C. Eijkemans, MSc; L.A van Herwerden, MD, PhD;
A.J.J.C. Bogers, MD, PhD; J.D.F. Habbema, PhD
Background—Bioprostheses are widely used as an aortic valve substitute, but knowledge about prognosis is still
incomplete. The purpose of this study was to provide insight into the age-related life expectancy and actual risks of
reoperation and valve-related events of patients after aortic valve replacement with a porcine bioprosthesis.
Methods and Results—We conducted a meta-analysis of 9 selected reports on stented porcine bioprostheses, including
5837 patients with a total follow-up of 31 874 patient-years. The annual rates of valve thrombosis, thromboembolism,
hemorrhage, and nonstructural dysfunction were 0.03%, 0.87%, 0.38%, and 0.38%, respectively. The annual rate of
endocarditis was estimated at 0.68% for .6 months of implantation and was 5 times as high during the first 6 months.
Structural valve deterioration was described with a Weibull model that incorporated lower risks for older patients. These
estimates were used to parameterize, calibrate, and validate a mathematical microsimulation model. The model was used
to predict life expectancy and actual risks of reoperation and valve-related events after implantation for patients of
different ages. For a 65-year-old male, these figures were 11.3 years, 28%, and 47%, respectively.
Conclusions—The combination of meta-analysis with microsimulation enabled a detailed insight into the prognosis after
aortic valve replacement with a bioprosthesis for patients of different ages. This information will be useful for patient
counseling and clinical decision making. It also could serve as a baseline for the evaluation of newer valve types.
(Circulation. 2001;103:1535-1541.)
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Nearly 40 years after the pioneering efforts of Starr andEdwards in heart valve replacement, a wide variety of
mechanical, bioprosthetic, and human tissue prostheses are
now available for clinical use. Mechanical valves have a
greater durability and consequently lower reoperation rates
than other valve types. However, they are associated with a
greater risk of thromboembolism, which necessitates regular
anticoagulation with the concomitant risk of hemorrhage. In
contrast, bioprostheses have a low thrombogeneity, which in
most patients obviates the need for regular anticoagulation
and consequently reduces hemorrhagic accidents. However,
the main factor limiting their use is the propensity to undergo
tissue degeneration, often necessitating reoperation. Human
tissue valves have a relatively low rate of thromboembolism
and endocarditis. However, the long-term incidence of struc-
tural valve deterioration (SVD) of these valves is uncertain,
and human valves are scarce.1–3
With the aging of the general population, the number of
elderly patients requiring aortic valve replacement has in-
creased rapidly during recent years. Hence, the choice and
long-term performance of a valve prosthesis becomes of
paramount importance. Currently, bioprostheses are recom-
mended for elderly patients who do not have risk factors for
thromboembolism. These valves may also be used in younger
patients presenting with a contraindication to long-term
anticoagulation.3
Because of the limited life expectancy (LE) of elderly
patients, the benefits of avoiding anticoagulation may out-
weigh the disadvantages of a possible reoperation, ie, the
valve will probably outlive the patient. However, in younger
patients, reoperations will be frequent, and reoperation-free
LE and event-free LE are important considerations in making
decisions about implantation.
The purpose of this study was to provide insight into the
prognosis of patients of different ages after implantation with
a stented porcine bioprosthesis. We incorporated data from
various smaller clinical studies in a mathematical microsimu-
lation model.
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We conducted a literature search of the PubMed and Medline
databases for the period January 1990 to December 1999. The terms
used for the search were both MeSH terms and the text words “heart
valve prostheses,” “aortic valve,” or “bioprostheses” in combination
with “porcine,” “stented,” “Hancock,” “Carpentier-Edwards,” or
“modified orifice.” The search was limited to “human” and to the
English language. We then screened the titles and abstracts of the
remaining studies to select those that examined the valve-related
events, outcomes, or survival of patients after aortic valve replace-
ment with a bioprosthetic valve. Reports that considered stentless
and pericardial valves were excluded during this process. The
references in the reports were cross-checked for other potentially
relevant studies. This resulted in 53 published reports.
We stipulated 5 criteria to obtain a group of similar studies: (1)
studies that described 1 or more of the following stented porcine
bioprostheses: Carpentier-Edwards standard and Carpentier-
Edwards supra-annular valves (Baxter Healthcare Corp) or Hancock
standard, Hancock modified orifice, and Hancock II valves
(Medtronic Inc); (2) isolated valve implantation in the aortic posi-
tion; (3) valves $19 mm in size implanted in patients .15 years of
age; (4) valve-related events defined according to the standard
definitions published in 19884 and 19965 (valve-related events
included valve thrombosis, thromboembolism, hemorrhage, endocar-
ditis, nonstructural dysfunction, and SVD; for this analysis, we only
included studies that contained data on at least 1 of these valve-
related events); and (5) no duplicate publication or overlapping
patient population. When these criteria were used, 44 studies were
excluded, leaving 9 studies for the present analysis.6–14
Data Extraction and Analysis
We reviewed the 9 reports to obtain the input data required for the
microsimulation model. The annual hazards of valve thrombosis,
thromboembolism, hemorrhage, and nonstructural dysfunction were
assumed to be constant over time. Hence, combined estimates of the
linearized occurrence rates for these events were calculated as the
ratio of the sums of the number of events and patient-years of
follow-up in the individual reports. The combined mortality and
reoperation rates after an event were similarly calculated.
Pooling of time-to-event curves was performed for survival,
freedom from endocarditis, and SVD. Published curves were
scanned and enlarged in a graphical computer package. The heights
of these curves were measured at each year, and corresponding
survival probabilities were calculated with their complementary
log-log transformations. These transformed probabilities were
pooled with weighting according to the estimated number of patients
at risk at each year and transformed back to obtain a summary
curve.15 Homogeneity of the curves was assessed graphically and
judged satisfactory.
The risk of endocarditis was assumed to take 2 phases of constant
hazard, with a hazard during the first 6 months greater than the
subsequent period. Therefore, we fitted a 2-period exponential model
on the pooled freedom-from-endocarditis curve, which was based on
3 reports.7,10,13
The risk of SVD depended on the time elapsed since valve
replacement and the age of the patient at implantation. This relation-
ship was described by a Weibull model.16,17 This model is a
generalization of the exponential distribution to accommodate a
changing risk over time. The shape parameter of the Weibull model
was estimated from the average freedom-from-SVD curve, which
was pooled from 4 reports.7,8,12,13 The age effect was incorporated in
the scale parameter of the Weibull model, based on 1 study.12
Microsimulation Model
Parameters in the Model
We used the estimates from the meta-analysis to parameterize a
previously developed microsimulation model (Figure 1).18 The
model incorporates SVD (age dependent), other valve-related events
(valve thrombosis, thromboembolism, hemorrhage, endocarditis, and
nonstructural dysfunction), and the background mortality of aortic
valve recipients (non–valve-related deaths). The simulation model
calculates patient survival rates by superimposing the mortality
associated with valve-related events on a background mortality. The
background mortality may well exceed that of the general population
owing to the aortic valve disease as such, cardiomyopathy, and the
valve replacement procedure.19–21 Therefore, hazard ratios were
applied to the age-specific survival rates of the Dutch population to
calibrate the model outputs with the age-specific survival curves
obtained from the literature.12 Operative mortality was estimated as
1.5% for a 40-year-old man, increasing with odds ratios of 1.022 for
age (per year) and 1.7 for every reoperation.18,21
Evaluation and Validation
Microsimulation is a type of Monte Carlo simulation.17 For our
evaluations, 10 000 virtual life histories were randomly drawn. Age
at death and occurrence of events and reoperation were registered for
each simulated patient. This enabled us to calculate the LE, event-
free LE, and reoperation-free LE, as well as actual risks of valve-
related events and reoperation, for a patient of a given age and sex.
The model output was validated against the pooled survival curve, as
obtained from 3 reports.8,10,12
Sensitivity Analyses
We performed 1-way sensitivity analyses to investigate the effect of
uncertainty in the parameter estimates. When we varied the estimates
of valve-related events according to their 95% CIs, we found only
very small variations in event-free LE. We therefore defined larger
ranges for the valve-related events, ie, from half to double the
baseline parameter values. The mortality hazard ratio was assumed




The 9 selected reports contained data on 5837 bioprosthetic
valve recipients with a total follow-up of 31 874 patient-years
(Table 1).6–14 The majority of patients were male, and the
mean age of the population was 64.6 years, although differ-
ences between the component studies were noted. Most
patients were in New York Heart Association class III or IV
(on average 71%), and a coronary artery bypass graft was
present in approximately one third (on average 36%).
Data Extraction and Analysis
A summary of the meta-analysis is given in Table 2. Ade-
quate data on valve thrombosis were available in only 4
Figure 1. Structure of microsimulation model. After implantation
of bioprosthesis, valve-related events can occur, which can lead
to reoperation and mortality. Non–valve-related death indicates
background mortality.
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reports,7,9,11,13 which yielded 3 events from 9925 patient-
years of follow-up. Two of these patients died, giving a death
rate of 67% for this rare event. Assuming a constant hazard,
a linearized occurrence rate was calculated for each of 4 types
of valve complications, of which thromboembolism was the
highest with 0.87% per patient-year. The incidence of endo-
carditis was estimated as 0.68% per patient-year beyond the
first 6 months after valve replacement and 3.4% per patient-
year before that (ie, 5 times as high).
The average incidence of SVD was estimated by a Weibull
model, as shown in Figure 2. The formula for freedom from
SVD was S(t) 5e2(t/s)^b, where S(t) indicates the probability
of being free from SVD at time t, and s and b indicate the
scale and shape parameters in the Weibull model, respec-
tively. The value of s depended on age: s5 e2.1110.01123age, and
the value of b was 3.49. With these parameters, the median
time until SVD was 17.1 years for a 65-year-old patient.
Model Calibration
The simulation model was calibrated by comparing survival
curves produced by the model (for both males and females of
varying ages) with empirical survival curves of the corre-
sponding age ranges.12 Hazard ratios of 8.0, 3.6, 1.5, 1.1, and
1.0 were found adequate for the background mortality in men
aged 35, 45, 55, 65, and 75 years, respectively.
Model Validation
An overall impression of the validity of the model was
obtained by comparison of expected and observed overall
survival. The observed survival was obtained by pooling the
curves from 3 reports in which the mean age was 61.5
years.8,10,12 The expected survival was calculated with the
model for male and female patients aged 62 years. These
curves closely approximated the pooled survival curve (Fig-
ure 3, top).
Age-Specific Results
Survival curves were estimated for men of different ages at
implantation of the valve (Figure 3, bottom). The area under
each survival curve equals the LE. The LE decreases with
advancing age, ie, from 17.1 to 7.2 years for men aged 35 to
75 years. The reoperation-free LE and event-free LE show a
remarkable pattern: an increase to age 55 years, followed by
a decrease (Figure 4). The increase is caused by the age
dependency of the SVD risk (decreasing with age), whereas
the eventual decrease is caused by the dominating effect of
TABLE 1. Characteristics of 9 Studies Selected for Meta-Analysis of Prognosis After Implantation of a













Preop NYHA Class III
and IV, n (%)
CABG,
n (%)
1 (12) 1108 546 (49) 74 (8) 24–91 4 735 749 (68) *
2 (13) 429 309 (72) 64 (12) $18 3 000 * 152 (35)
3 (6) 843 490 (58) 69 (*) 16–91 5 093 704 (84) 365 (43)
4 (14) 1594 1124 (71) 60 (15) 16–94 10 212 908 (57) 545 (34)
5 (9) 536 391 (73) 64 (12) 18–86 2 276 393 (73) 213 (40)
6 (15) 165 116 (70) 67 (9) 27–87 551 127 (77) 32 (19)
7 (16) 571 * 59 (*) 15–85 3375 531 (93) *
8 (17) 196 163 (83) 48 (12) 17–70 1 368 167 (85) *
9 (8) 395 245 (62) 65 22–84 1 264 * 122 (31)
Total 5837 3384 (64) 64.6 15–94 31 874 3579 (71) 1429 (36)
pt-years indicates patient-years; preop, preoperative; and NYHA, New York Heart Association.
*Data not available.
TABLE 2. Summary of Meta-Analysis of Prognosis After Implantation of Stented Porcine






Outcome Freedom From Event, %
Death Rate Reop Rate At 5 Years At 10 Years
Valve thrombosis 3 0.030 0.67 0.33 99.8 99.7
Thromboembolism 277 0.869 0.19 0 95.7 91.6
Hemorrhage 113 0.382 0.21 0 98.1 96.2
Endocarditis 167 3.4/0.68* 0.34 0.55 96.0‡ 92.4‡
NSD 94 0.384 0.05 0.52 98.1 96.2
SVD 352 † 0.10 0.84 99.4‡ 85.2‡
LOR indicates linearized occurrence rate (or hazard); pt-years, patient-years; Reop, reoperation; and NSD,
nonstructural dysfunction.
*A 2-period exponential model was constructed for risk during and after the first 6 months after implantation.
†A Weibull model was constructed incorporating age dependency.
‡Percentages from summary survival curves.
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background mortality at older age. For a 65-year-old man, the
LE, reoperation-free LE, and event-free LE were 11.3, 9.5,
and 8.4 years, respectively.
We further calculated the actual lifetime risk of a reopera-
tion or a valve-related event after aortic valve replacement.
The lower these risks, the better the prognosis. As shown in
Figure 5, the probability of ever undergoing a reoperation or
experiencing a valve-related event rapidly decreased with age
at implantation, from 63% and 83% at 35 years to 11% and
24%, respectively, at 75 years.
Furthermore, we compared the LE of male bioprosthesis
recipients with the LE of men in the general Dutch popula-
tion. The relative LE increased with the age of valve
replacement (Figure 6). We also estimated the relative LE of
a hypothetical valve recipient, were he immune to valve-
related events. The relevant parameters in the model were set
to zero. This enabled us to quantify the impact of the
increased background mortality. This impact was large for
young patients (eg, 46% for 35-year-old men) and decreased
to 0% for 75-year-old men, corresponding to the decrease in
hazard ratio to 1. The difference between the curves in Figure
6 represents the loss in LE due to the occurrence of valve-
related events. This relative difference was ’12% for all
ages. On an absolute scale, the difference decreases with age.
Sensitivity Analyses
The event-free LE of a 65-year-old male patient is shown in
Table 3 for extreme values of the valve-related events while
other parameters are kept at baseline values. Changes in SVD
risk had the largest influence. A doubling of the median
failure time would increase the event-free LE by 1.5 years
(from 8.4 to 9.9 years) and a halving would reduce the
event-free LE by 2.8 years (from 8.4 to 5.6 years). Further-
more, increasing the hazard ratio associated with the back-
ground mortality from 1.1 to 1.5 resulted in an event-free LE
of 7.6 instead of 8.4 years.
Discussion
We used a meta-analysis of empirical data and a mathemat-
ical microsimulation model to predict the LE and actual
Figure 5. Actual risks of reoperation and of valve-related events
for men of different ages.
Figure 2. Average freedom from SVD as estimated from litera-
ture (pooled) and with Weibull model.
Figure 3. Survival after implantation of stented porcine biopros-
thesis. Top, Pooled estimate from literature (pooled) and pre-
dicted survival for 62-year-old men and women according to
model. Bottom, Predicted survival for men of different ages.
Figure 4. LE, reoperation-free LE (RFLE), and event-free LE
(EFLE) for men of different ages.
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lifetime risk of reoperation and valve-related events for
patients after implantation with a stented porcine bioprosthe-
sis. The microsimulation model generates the life histories of
a large number of virtual patients. Compared with standard
statistical methods, the added value of modeling is that it
provides detailed insights into the occurrence of valve-related
and non–valve-related events. For a 65-year-old man, for
example, the model predicted an LE of 11.3 years and a
lifetime risk of reoperation and a valve-related event of 28%
and 47%, respectively, after implantation with a bioprosthe-
sis. Such information will be useful for patient counseling and
for the surgeon and patient in making decisions. We envision
being able to present a user-friendly version of the model on
the Internet in the near future that could serve as a bedside
tool to the surgeon. The model results may also serve as a
baseline for the evaluation of newer valve types.
We chose 5 types of stented porcine bioprostheses, both
first and second generation, which were not markedly differ-
ent from one another. The Hancock standard prosthesis and
the Carpentier-Edwards standard prosthesis, 2 of the initial
stented porcine valves, were introduced in the early 1970s.2,22
The composite Hancock modified orifice prosthesis was
designed to improve hemodynamic performance by substitut-
ing the septal leaflet with a nonseptal leaflet from a second
porcine valve.6,23 In contrast to the above, the second-
generation Carpentier-Edwards supra-annular bioprosthesis
and the Hancock II bioprosthesis were introduced in the
1980s and incorporated several considered improvements,
including a supra-annular configuration, to maximize the
effective orifice of the prosthesis.7,8
Similarities in the performance of these valve types have
been documented in the literature. A randomized prospective
comparison of the Hancock standard and the Carpentier-
Edwards standard valves showed no clear difference in
durability or other valve-related complications after 10
years.22 Also, no important differences were found in dura-
bility or other valve-related complications between the Han-
cock modified orifice valve and the 2 standard valve types.23
The second-generation porcine bioprostheses (Carpentier-
Edwards supra-annular, Hancock II) were designed to im-
prove clinical performance by reducing the incidence of
SVD. However, Jamieson and others24 failed to demonstrate
clinically relevant differences with regard to freedom from
SVD between the Carpentier-Edwards standard and
Carpentier-Edwards supra-annular valves, except for the 21-
to 40-year-old age group. The risk of valve-related compli-
cations with the Hancock II prosthesis has been reported to be
similar to the previously mentioned valve types.25,26 How-
ever, the limited improvement in durability of the second-
generation valves could be related to enhanced surveillance
and early intervention.
Ideally, for the application of simulation methodology, a
sufficiently comprehensive “super data set” should be ana-
lyzed.19 Such a data set should contain detailed information
on patients who underwent aortic valve replacement, have
complete and long-term follow-up for all patients, and con-
sider all relevant valve-related events. However, no such
databases are available as yet, although reports on larger
series with long-term follow-up have become more fre-
quent.27,28 We pooled the results of selected reports that
satisfied strict criteria and calculated quantitative estimates
for the parameters of interest (Table 2). An advantage of
pooling was that the estimates represented the experience of
many institutions with possibly slightly varying patient pop-
ulations. Single-center results may be less generalizable
because of typical patient populations and unique surgical
practices.
Figure 6. LE of men with aortic valve disease relative to that of
men in the general population for different ages.
TABLE 3. Summary of Sensitivity Analyses
Parameter Baseline Estimate*
Plausible Range† Event-Free LE, y
Favorable Unfavorable Favorable Unfavorable
Valve thrombosis 0.030 0.015 0.06 8.45 8.43
Thromboembolism 0.869 0.43 1.74 8.67 8.02
Hemorrhage 0.382 0.19 0.76 8.54 8.24
Endocarditis 0.680 0.34 1.36 8.66 8.05
NSD 0.384 0.19 0.77 8.53 8.25
SVD 17.1‡ 34.2‡ 8.5‡ 9.89 5.57
Hazard ratio 1.1 1 1.5 8.66 7.66
NSD indicates nonstructural dysfunction.
*The event-free LE was 8.44 years in the baseline analysis.
†The plausible range was defined by a halving or doubling of the baseline estimate.
‡Median time until SVD according to the Weibull model.
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Standard actuarial statistical techniques (eg, Kaplan-Meier)
have been used in many studies to assess the survival of
patients and the performance of valve prostheses, while
“actual” analysis has recently gained interest.29 For survival,
the actuarial and actual methods provide identical estimates.
However, when the actuarial method is applied to nonfatal
complications, such as SVD, the risk described is that which
patients would experience provided they were immortal.
Patients with valve disease have relatively high annual risks
of death. Hence, a more relevant estimate of valve failure is
the actual percentage of patients who will experience an event
before they die.27,29,30 The simulation model provides esti-
mates of the actual risk of reoperation and of valve-related
events according to age (Figure 5). This information is more
meaningful than actuarial risks or actual risks for “average”
patients. The estimates by Grunkemeier and colleagues29 for
the actual risk of ever experiencing an SVD (20% for the age
group 70 to 73 years and 40% for the 59- to 63-year-old age
group) were rather similar to our model estimates (18% for
71-year-old and 42% for 61-year-old males, respectively).
The microsimulation model calculates patient survival
rates by superimposing the mortality associated with valve-
related events on a background mortality rate. The back-
ground mortality is the non–valve-related mortality of the
valve recipients. It was previously assumed that in the
absence of morbid valve events, patients would follow
the trajectory of the general population.18 This assumption
may not be tenable, because valve disease, cardiomyopathy,
and the valve replacement procedure per se may cause higher
non–valve-related mortality than noted in the general popu-
lation.19–21 By applying age-specific hazard ratios to the
age-specific survival curves of the general population, we
aimed to obtain a more accurate prediction of patient prog-
nosis. For young patients, the increase in background mor-
tality was substantial compared with the general population
(eg, a 36% lower LE for a 45-year-old man).
Limitations of our microsimulation model included that
certain structural assumptions had to be made. For example,
a constant hazard was assumed for valve thrombosis, throm-
boembolism, hemorrhage, and nonstructural dysfunction,
where in fact, these hazards may be time and age dependent.
Furthermore, endocarditis risk was assumed to be piecewise
constant before and after 6 months of follow-up, and SVD
risk was described with a Weibull model. Additional studies
need to address these assumptions. Furthermore, survival
after aortic valve replacement will not only depend on age
and sex but also on many risk factors, including preoperative
New York Heart Association class and the presence of
coronary heart disease.
In addition to structural assumptions, uncertainty existed in
parameter values owing to small or moderate numbers of
events. The time to SVD was the most important factor for
event-free LE. This is of interest in assessing the value of
newer bioprostheses, eg, stentless types.31,32 When more data
become available on such valves, these can easily be included
in our model to quantify the impact on patient prognosis.
Furthermore, a change in background mortality resulted in a
marked variation in the LE. This illustrates the need for
incorporation of more detailed information on the clinical
characteristics of the patients into the model. Also, updating
of the model with the growing experience with bioprostheses
is essential to provide valid estimates of prognosis in the
future.
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